Sold as Pur-Wash. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Purified Water (sold as Pur-Wash), first approved Sep 1, 2011, with 0 new uses approved and 0 published complete response letters.
| Auricular Indwelling Needles Added to Diosmin/Hesperidin for Grade I-II Internal Hemorrhoids With Heat-Toxin SyndromeInternal Haemorrhoids · University of Medicine and Pharmacy at Ho Chi Minh City | Not applicable | Not yet recruiting | Oct 27, 2026 |
| VATS or Intrapleural Enzymatic Therapy for Patients With Empyema.Empyema, Pleural, Pleural Infections · Amsterdam UMC | Phase 4 | Recruiting | Oct 21, 2026 |
| THBC/CGF for Alveolar Bone Regeneration: A Real-World StudyAlveolar Bone Loss, Alveolar Ridge Resorption After Extraction · Stomatological Hospital Affiliated with Fujian Medical University | Not applicable | Recruiting | Aug 21, 2026 |
| Traditional Chinese Medicine for the Prevention of Radiotherapy-Induced Oral Mucositis (RTOM)Radiotherapy-Induced Oral Mucositis, Stomatitis · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 3 | Not yet recruiting | Apr 22, 2026 |
| Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer PatientsHead and Neck Squamous Cell Carcinoma, Locally Advanced Rectal Cancer · Fondazione del Piemonte per l'Oncologia | Not applicable | Recruiting | Apr 7, 2026 |
| Efavirenz for the Treatment of Creutzfeldt-Jakob DiseaseCreutzfeldt-Jakob Disease · Xuanwu Hospital, Beijing | Phase 3 | Recruiting | Mar 19, 2026 |
| A Study on the Efficacy of Environmental Probiotics in Patients With Cat Hair AllergiesCat Allergy (Disorder), Allergic Rhinitis · Second Affiliated Hospital, Zhejiang University, School of Medicine | Not applicable | Enrolling by invitation | Aug 11, 2025 |
| Instant Flush Redness Clinical Efficacy StudySensitive Skin · ChinaNorm | Not applicable | Not yet recruiting | Jul 16, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 1, 2011 | Pur-WashNDA 22305 · New formulation or manufacturer | Niagara Pharms | 5 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
